Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2020-05-31 Major Shareholding Noti…
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 4 pages 416.5KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001, detailing changes in relevant interests and association of a substantial shareholder. It reports changes in shareholding levels and cessation of substantial holding status. This matches the definition of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document is not a financial report, earnings release, or management information, but a regulatory disclosure about shareholding changes.
2020-05-31 English
MYX signs license agreement for contraceptive in Australia 2 pages 153.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 28 May 2020 regarding Mayne Pharma entering into a 20-year license and supply agreement for a novel oral contraceptive in Australia. It discusses the terms of the agreement, product details, market information, and quotes from company executives. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a corporate announcement about a commercial agreement and partnership, not a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a typical corporate press release announcing a business transaction or partnership. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and miscellaneous filings that do not fit other specific categories. The document length is over 5,000 characters, so it is not a mere report publication announcement. Confidence is high given the clear nature of the content.
2020-05-27 English
Becoming a substantial holder 7 pages 443.8KB
Major Shareholding Notification Classification · 95% confidence The document is titled 'Form 603' and references the Corporations Act 2001, Section 671B, which pertains to notices of initial substantial holders. It details the substantial shareholding of Lazard Asset Management Pacific Co in Mayne Pharma Group Limited, including voting power, relevant interests, registered holders, consideration paid, and associates. The content is a formal notification of a substantial shareholding crossing a threshold, consistent with regulatory requirements for major shareholding disclosures. There is no financial performance data, management discussion, or report publication. The document is not an annual or interim report, earnings release, or any other financial report type. It fits the definition of a Major Shareholding Notification (MRQ). The document length (9945 characters) supports it being a full notification rather than a brief announcement. Therefore, the correct classification is MRQ with high confidence.
2020-05-24 English
Mayne Pharma submits NDA for E4/DRSP to the FDA 3 pages 116.1KB
Regulatory Filings Classification · 95% confidence The document is a joint press release announcing the submission of a New Drug Application (NDA) to the FDA by Mayne Pharma and Mithra Pharmaceuticals. It discusses the product, market potential, and includes forward-looking statements. There are no financial statements, regulatory certifications, or detailed financial data. The document is a corporate announcement about a regulatory filing (NDA submission) rather than a financial report or detailed regulatory filing. It is not an earnings release, annual report, or any other detailed financial or governance document. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-04-15 English
Change of CFO and Company Secretary 2 pages 149.8KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement regarding the resignation of the Group Chief Financial Officer and the appointment of an interim CFO and a new Company Secretary. It focuses on management changes and does not contain financial statements, earnings data, or detailed financial analysis. The content is about personnel changes in senior management positions, which fits the category of Board/Management Information (MANG). The document length is 4532 characters, which is consistent with a typical announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2020-03-19 English
Change in substantial holding 7 pages 273.5KB
Regulatory Filings
2020-03-15 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.